- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Angus Worthing: The Benefits of Biosimilars
Angus Worthing, MD, FACR, FACP, discusses the benefits of biosimilar medicines.
Transcript:
What benefits do biosimilars offer to providers and to the healthcare system?
Biologic drugs have really revolutionized the practice [and] treatment of rheumatoid arthritis, and other autoimmune diseases, but that has come at a tremendous cost and oftentimes the price is a lack of access to drugs. So, it’s one of the things that gets me up out of bed in the morning, and what I really like my job for, is that I can see people, and diagnose them, and put a treatment plan in place that’s going to get them back to work and reduce their aching joints. But, it’s heartbreaking when people can’t get access to the drugs because they’re too expensive. The best thing that biosimilars give to providers, and also to patients, is the promise of increased access to care, so that everybody who needs one of these drugs can get on it, afford it, and have it also be affordable for society at large—that’s the benefit of biosimilars. In short, that’s the benefit of biosimilars.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
